EL7.AI
StocksMedium•16 November 2026•
1 min read

Aclaris Therapeutics Phase 2 Trial for Atopic Dermatitis Fails Primary Endpoint

Key Facts

1Aclaris Therapeutics announced that the Phase 2 ADMIRATION trial for bosakitug did not achieve its primary endpoint.
2The drug failed to achieve the primary endpoint of percent change in Eczema Area and Severity Index (EASI) score at week 24.
3The company plans to pivot focus toward developing its oral kinase inhibitors and ATI-052 bispecific antibody.

Aclaris Therapeutics announced that the Phase 2 ADMIRATION trial for bosakitug did not achieve its primary endpoint. According to a company statement via GlobeNewswire, the drug failed to show a statistically significant percent change in the Eczema Area and Severity Index (EASI) score at week 24 compared to the control group.

The company plans to pivot its focus toward developing its oral kinase inhibitors and ATI-052 bispecific antibody following the trial results. ACRS closed at $3.92 on November 13, 2026, prior to the announcement regarding the clinical setback for its atopic dermatitis candidate.

Open on chart